Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGFR | P43088 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25697265 | 1.00 | CFTR (0.31) | CFTRMEN1KMT2ARXFP1KDM4E | |
| SCHEMBL25687417 | 0.87 | SCN9A (0.36) | CFTR | |
| SCHEMBL25687420 | 0.87 | SCN9A (0.36) | CFTR | |
| SCHEMBL23958803 | 0.87 | SCN9A (0.36) | CFTR | |
| SCHEMBL25697304 | 0.84 | ACSS2 (0.32) | MEN1KMT2ARXFP1KDM4ERAB9A | |
| SCHEMBL25687476 | 0.80 | SCN9A (0.38) | CFTRKMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL30007116 | 0.80 | SCN9A (0.38) | CFTRKMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL25687377 | 0.80 | SCN9A (0.38) | CFTRMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL23958713 | 0.80 | SCN9A (0.38) | CFTRKMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL25687474 | 0.80 | SCN9A (0.38) | CFTRKMT2ARXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | CFTR 508/4885MEN1 940/4885KMT2A 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.